Get the Stockscreener App
2.96
2.78%
0.08
Atyr Pharma Inc stock is traded at $2.96, with a volume of 1.13M.
It is up +2.78% in the last 24 hours and down -25.16% over the past month.
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.
See More
Previous Close:
$2.88
Open:
$2.82
24h Volume:
1.13M
Relative Volume:
0.91
Market Cap:
$263.02M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-8.64%
1M Performance:
-25.16%
6M Performance:
+66.29%
1Y Performance:
+0.00%
1-Day Range:
$2.82
$2.99
1-Week Range:
$2.82
$3.34
52-Week Range:
$1.42
$4.66
Atyr Pharma Inc Stock (ATYR) Company Profile
Name
Atyr Pharma Inc
Sector
Industry
Phone
(858) 731-8389
Address
10240 SORRENTO VALLEY ROAD, SAN DIEGO
Compare ATYR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATYR
Atyr Pharma Inc
|
2.96 | 263.02M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
483.49 | 124.48B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
625.60 | 67.45B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
583.62 | 35.60B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
266.83 | 34.53B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
274.78 | 29.15B | 3.81B | -644.79M | -669.77M | -6.24 |
Atyr Pharma Inc Stock (ATYR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-18-25 | Initiated | Leerink Partners | Outperform |
| Jan-06-25 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-04-24 | Initiated | Wells Fargo | Overweight |
| Sep-05-24 | Initiated | Jefferies | Buy |
| Jul-05-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Oct-12-21 | Initiated | RBC Capital Mkts | Outperform |
| Sep-21-21 | Initiated | Piper Sandler | Overweight |
| May-10-21 | Initiated | Laidlaw | Buy |
| Aug-17-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Mar-04-20 | Initiated | ROTH Capital | Buy |
| Mar-02-20 | Initiated | Oppenheimer | Outperform |
| Feb-14-18 | Downgrade | JP Morgan | Neutral → Underweight |
| Sep-07-17 | Initiated | Piper Jaffray | Overweight |
| Dec-13-16 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-16-15 | Initiated | Citigroup | Neutral |
| Jun-01-15 | Initiated | Citigroup | Buy |
| Jun-01-15 | Initiated | JP Morgan | Overweight |
View All
Atyr Pharma Inc Stock (ATYR) Latest News
Charles Schwab Investment Management Inc. Takes Position in Atyr PHARMA INC (NASDAQ:ATYR) - Defense World
ATyr Pharma : ClearOne, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results - MarketScreener
aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
aTyr Pharma Strengthens Drug Development Team with New Equity Compensation Package - Stock Titan
Is aTyr Pharma (ATYR) The Hot Biotech Stock Under $5? - Insider Monkey
aTyr Pharma appoints new head for efzofitimod program By Investing.com - Investing.com South Africa
aTyr Pharma appoints new head for efzofitimod program - Investing.com
ATyr Pharma Announces The Appointment Of Dalia R. Rayes As Head Of Commercial, Global Efzofitimod Franchise - MarketScreener
aTyr Pharma Announces the Appointment of Dalia R. Rayes as Head of Commercial, Global Efzofitimod Franchise - GlobeNewswire
25-Year Pharma Veteran Joins aTyr to Launch First New Sarcoidosis Treatment in 70 Years - Stock Titan
Victory Capital Management Inc. Buys New Stake in Atyr PHARMA INC (NASDAQ:ATYR) - Defense World
Insider Buying: Jane Gross Acquires Additional Shares of aTyr Ph - GuruFocus.com
10 Hot Biotech Stocks Under $5 - Insider Monkey
Is aTyr Pharma (ATYR) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Atyr, FDA align on efzofitimod trial analysis for pulmonary sarcoidosis - Sarcoidosis News
aTyr Pharma (ATYR) Stock Soars 24% on Promising Drug Developments - Markets Insider
Reviewing Atyr PHARMA (NASDAQ:ATYR) & Windtree Therapeutics (NASDAQ:WINT) - Defense World
HC Wainwright Reaffirms Buy Rating for Atyr PHARMA (NASDAQ:ATYR) - Defense World
Atyr PHARMA INC (NASDAQ:ATYR) Receives Average Recommendation of “Buy” from Brokerages - Defense World
Earnings call transcript: aTyr Pharma Q4 2024 beats EPS expectations By Investing.com - Investing.com Australia
aTyr Pharma’s Earnings Call Highlights Progress and Challenges - TipRanks
aTyr Pharma: Good Safety Data In Pulmonary Sarcoidosis, Institutions Are Accumulating - Seeking Alpha
Cantor Fitzgerald maintains Overweight on aTyr Pharma stock - Investing.com India
aTyr Pharma Inc (ATYR) Q4 2024 Earnings Call Highlights: Strong Cash Position and Promising ... - Yahoo Finance
aTyr Pharma shares fall as Q4 loss narrows - Investing.com India
aTyr Pharma Inc (ATYR) Q4 2024 Earnings Call Highlights: Strong Cash Position and Promising ... By GuruFocus - Investing.com Canada
aTyr Pharma Inc (ATYR) Q4 2024 Earnings Call Highlights: Strong Cash Position and Promising Clinical Developments - GuruFocus.com
aTyr Pharma Reports 2024 Results and Strategic Progress - TipRanks
Earnings call transcript: aTyr Pharma Q4 2024 beats EPS expectations - Investing.com
aTyr Pharma Inc Reports Q4 2024 Earnings: EPS of -$0.18 Beats Es - GuruFocus.com
aTYR PHARMA INC SEC 10-K Report - TradingView
aTyr Pharma Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Atyr Pharma: Q4 Earnings Snapshot - mySA
aTyr Pharma shares fall as Q4 loss narrows By Investing.com - Investing.com South Africa
ATYR PHARMA Earnings Results: $ATYR Reports Quarterly Earnings - Nasdaq
aTyr Pharma Announces Fourth Quarter and Full Year 2024 Results and Provides Corporate Update - GlobeNewswire
aTyr Pharma Hits Major Phase 3 Milestone with $94M War Chest for Sarcoidosis Drug - StockTitan
aTyr Pharma’s efzofitimod shows promise in ILD treatment By Investing.com - Investing.com Canada
aTyr Pharma’s efzofitimod shows promise in ILD treatment - Investing.com India
aTyr Pharma Announces Publication Demonstrating - GlobeNewswire
aTyr Pharma Announces Publication Demonstrating Efzofitimod's Immunomodulatory Activity in Science Translational Medicine - The Manila Times
Breakthrough: New Science Study Reveals How Efzofitimod Fights Chronic Inflammation - StockTitan
aTyr Pharma, Inc. to Host Earnings Call - ACCESS Newswire
Atyr Pharma Shares Rise After Lung Disease Treatment Passes Safety Review - MarketWatch
aTyr Pharma: Attractive Buy Opportunity Amid Positive Phase 2 Data and Anticipated Phase 3 Catalysts - TipRanks
aTyr rises after safety update on lead program - Seeking Alpha
aTyr Pharma Announces Fourth Positive DSMB Review for - GlobeNewswire
aTyr Pharma Announces Fourth Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis - The Manila Times
Can This Rare Disease Drug's Perfect Safety Record Signal a Breakthrough for Sarcoidosis Patients? - StockTitan
Atyr Pharma Inc Stock (ATYR) Financials Data
There is no financial data for Atyr Pharma Inc (ATYR). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
2.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):